The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

Analyst Derek Archila of Wells Fargo assigned a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the ...

European regulators on Friday upheld its negative opinion on Apellis Pharmaceuticals' (NASDAQ:APLS) proposed treatment for ...

We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to ...

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Both Izervay and Syfovre are eye injections used to treat geographic atrophy caused by AMD. They work similarly to one another to manage this condition. Because of this, they can cause some ...

Apellis Pharmaceuticals (APLS) is down more than -9% after the European Medicines Agency upheld its negative opinion on the marketing authorization for the company’s Syfovre eye drug. Frontline Plc ...

Apellis reported robust growth in Q2 2024, with its drugs SYFOVRE and EMPAVELI performing well. SYFOVRE achieved over $0.5 billion in sales since its launch and $155 million in net product revenue ...

Apellis Pharmaceuticals (APLS) closed down more than -12% after the European Medicines Agency upheld its negative opinion on the marketing authorization for the company’s Syfovre eye drug. Frontline ...